Bigmar Receives $1 Million Order From American Pharmaceutical Partners for Generic Oncology Drugs; Part of Multi-Million Dollar Order to be Shipped Over Next 12 Months.

JOHNSTOWN, Ohio--(BUSINESS WIRE)--Aug. 5, 1999--

BIGMAR, Inc. (Nasdaq SmallCap Market: BGMR) today announced that it has received its first order under its recently announced distribution and marketing relationship with American Pharmaceutical Partners (APP). The initial order, valued at $1.0 million, covers three of Bigmar's market-ready generic oncology drugs, Daunorubicin Hydrochloride, Methotrexate, and Leucovorin Calcium, in varying dosages.

Shipment of the initial order is scheduled for September 1, 1999. It is contemplated that shipments for an additional $4 million of these drugs will occur through August 31, 2000. APP has also indicated its plans to order additional generic oncology products from Bigmar which provide cost-effective therapies used for remission induction in various types of cancer.

John G. Tramontana, Chairman and Chief Executive Officer of Bigmar, commented, "This order represents a major step forward in achieving revenue growth for Bigmar. Based on our discussions we are hopeful that this agreement with APP will lead to others for some of Bigmar's additional oncology products. All of us at Bigmar have been working toward this goal for quite some time and we are very pleased to see our efforts rewarded."

Bigmar has received a total of seven Abbreviated New Drug Application ("ANDA") approvals from the Food and Drug Administration for its line of generic oncology drugs. The products involved under the agreement with APP will be produced at Bigmar's FDA-inspected Barbengo, Switzerland manufacturing facility. This facility utilizes barrier isolation technology to manufacture FDA-approved parenteral drug products. To management's knowledge, Bigmar is currently the only company applying this highly automated containment technology to the manufacture of generic drugs.

Jeffrey M. Yordon, President of American Pharmaceutical Partners, stated, "We entered this agreement with Bigmar because of its ability to manufacture high quality injectable oncology products and because they have been successful in receiving approvals in a timely manner. We are confident they will prove to be an excellent strategic partner and assist us in positioning APP as a significant supplier of products to the oncology market in the United States." Mr. Yordon continued, "APP has established solid contractual relationships with major customers in this market segment and anticipates strong sales of the Bigmar products. These products are very strategic and fit well with APP's current and future product introductions. We anticipate that Bigmar will develop additional strategic products to augment APP's internal product development in the future."

BIGMAR, Inc.'s strategy is to supply world markets with a line of high quality, affordably priced pharmaceutical products with a focus on oncology. The Company has distribution rights to more than 20 generic oncological products and seven products approved by the FDA, which are manufactured in the Company's state-of-the-art facilities in Switzerland. The Company markets its products through partnerships with pharmaceutical distributors in Europe and the United States and focuses on off-patent oncological drugs.

American Pharmaceutical Partners, Inc., is a privately held integrated pharmaceutical company with over 750 employees. APP is one of the leading manufacturers of injectable pharmaceuticals in the United States with facilities in Los Angeles, California; Schaumburg, Illinois; Melrose Park, Illinois; Grand Island, New York and Toronto.

Forward-looking statements involve known and unknown risks, uncertainties and other factors as detailed in the Company's SEC reports and filings, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied in such forward-looking statements.